Tagged with M

Americas Writing in the March edition of DIA’s Global Forum magazine, EMD Serono’s Ana Padua outlines the findings of a recent study into accelerated regulatory pathways in Latin America which aim to reduce approval timelines for innovative medicines.   The Latin America region offers a number of registration pathways to accelerate…

Global The global rush to secure access to COVID-19 vaccines has led to accusations that richer countries are hoarding supply at the expense of poorer nations. While some are calling for a relaxation of intellectual property (IP) to allow less-developed nations to vaccinate their populations, Big Pharma is resistant, arguing that…

Singapore Nawal Roy of global digital health platform Holmusk which aims to establish data as a core utility to the treatment of behavioural health disorders explains the challenges of working in behavioural health, why continuing inflows of talent and capital to the space are so important, and the benefits of basing…

Japan Following on from our recent compilations of 2020 new drug approvals in the USA, China, and Switzerland, see below for the Japanese PMDA’s new drug approvals list for April-October 2020. Made with Visme Infographic Maker  

USA Dan Leonard, president and CEO of the Association for Accessible Medicines (AAM) since August 2020, outlines his key agenda priorities as head of the USA’s largest generic industry body, how the COVID-19 pandemic has altered the discussion around generics and essential medicines, and his hopes for the Biden administration  …

Dominican Republic Alejandro Mora, Ferrer’s country manager for Central America & Caribbean, discusses the complexity of the region’s healthcare systems, the company’s strategy to compete against local players, and the importance for multinational companies of going beyond the pill in the region, making efforts to be sustainable and help the environment.  …

USA PhRMA’s Stephen J. Ubl outlines two ways in which the new US presidency can help lower healthcare costs and why biopharmaceutical companies support changes to the system that can lower US patients’ out-of-pocket spending and continue to drive innovation.   By bringing an end to the pandemic and lowering out-of-pocket…

China The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and dMed’s R&D collab; and investment news on Clover Biopharmaceuticals, Sciwind Biosciences, and Gensciences.   AstraZeneca signs deal with Chinese biotech Junshi Biosciences to market anti-PD-1 cancer drug in China https://www.biopharma-reporter.com/Article/2021/03/01/AstraZeneca-betting-on-China-s-PD-1-cancer-market AstraZeneca has signed a…

Singapore ASLAN Pharmaceuticals is a clinical-stage immunology-focused biopharmaceutical company. CEO Dr Carl Firth reveals why the company has shifted its focus from oncology to autoimmune diseases. He explains why their lead asset has the potential to compete with Sanofi’s blockbuster Dupixent and why ASLAN decided to delist from the Taiwan Stock…

Switzerland After 15 years as director at the Friedrich Miescher Institute for Biomedical Research (FMI) (2004-2019) and even longer as the group leader at her own research lab, Professor Susan M. Gasser was appointed director of the Foundation of the Swiss Institute for Experimental Cancer (ISREC), in a way closing the…

Mexico The latest from Mexico’s fight against COVID-19, including news of vaccine tourism into the US, how China’s CanSino is filling the gaps left by Western companies, and AMLO’s call for UN intervention on vaccine rollout.   The Mexican Elites Who Are Traveling to the U.S. to Get Vaccinated (Slate) https://slate.com/technology/2021/02/covid-19-vaccine-tourism-mexico-elites.html…

Switzerland Dipharma SA is a Swiss specialty pharmaceutical company, developing improved generics medicines for rare metabolic diseases. Founder & CEO Marc-Olivier Geinoz discusses why the company has chosen to compete in the largely unexplored rare diseases generics space, its direct presence in the German market, and the opportunities inherent in metabolic…